89Zr-DFO-AR9.6

89Zr-DFO-AR9.6 is a radiolabeled monoclonal antibody-based imaging agent designed for positron emission tomography (PET). It consists of the AR9.6 antibody (a human or murine monoclonal antibody that targets mucin-16, also known as MUC16 or CA125), conjugated with desferrioxamine (DFO) as a chelator, and labeled with the radioisotope zirconium-89 (^89Zr). The antibody, AR9.6, binds specifically to MUC16-expressing tumor cells and blocks the interaction between MUC16 and ErbB receptors, suppressing downstream oncogenic signaling. This radiotracer enables noninvasive detection and monitoring of MUC16-positive tumors, such as high-grade serous ovarian cancer and pancreatic ductal adenocarcinoma, allowing precise imaging and potentially guiding therapy with AR9.6 antibody. Preclinical studies have demonstrated specific tumor uptake, excellent PET imaging quality, and utility in tracking metastasis and lymph node involvement in relevant cancer models[1][4].

Other names

89Zr-DFO-huAR9.689Zr-DFO-muAR9.6